TVTX vs. AXSM, ADMA, ZLAB, AKRO, PCVX, PTCT, CYTK, RYTM, KRYS, and MRUS
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Vaxcyte (PCVX), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Travere Therapeutics vs. Its Competitors
Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Axsome Therapeutics presently has a consensus target price of $172.33, suggesting a potential upside of 65.29%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 110.91%. Given Travere Therapeutics' higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than Axsome Therapeutics.
Axsome Therapeutics received 393 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 70.97% of users gave Axsome Therapeutics an outperform vote while only 61.94% of users gave Travere Therapeutics an outperform vote.
Axsome Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Axsome Therapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for Travere Therapeutics. Axsome Therapeutics' average media sentiment score of 0.28 beat Travere Therapeutics' score of 0.11 indicating that Axsome Therapeutics is being referred to more favorably in the media.
Axsome Therapeutics has a net margin of -64.39% compared to Travere Therapeutics' net margin of -82.88%. Axsome Therapeutics' return on equity of -272.80% beat Travere Therapeutics' return on equity.
Summary
Axsome Therapeutics beats Travere Therapeutics on 15 of the 19 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TVTX) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy TVTX Stock Free TVTX Stock Alerts